Q2 EPS Estimate for MAIA Biotechnology Lifted by Analyst

MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) – Diamond Equity raised their Q2 2026 earnings per share (EPS) estimates for shares of MAIA Biotechnology in a note issued to investors on Monday, May 18th. Diamond Equity analyst H. Diamond now expects that the company will post earnings per share of ($0.11) for the quarter, up from their prior forecast of ($0.22). The consensus estimate for MAIA Biotechnology’s current full-year earnings is ($0.69) per share. Diamond Equity also issued estimates for MAIA Biotechnology’s Q3 2026 earnings at ($0.12) EPS and FY2026 earnings at ($0.52) EPS.

MAIA Biotechnology (NYSEAMERICAN:MAIA) last announced its earnings results on Monday, May 11th. The company reported ($0.14) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.18) by $0.04.

MAIA Biotechnology Price Performance

Shares of NYSEAMERICAN:MAIA opened at $1.23 on Wednesday. MAIA Biotechnology has a 1 year low of $0.87 and a 1 year high of $3.19. The firm has a market capitalization of $74.78 million, a price-to-earnings ratio of -1.84 and a beta of 0.21. The business’s 50 day moving average price is $1.36 and its 200-day moving average price is $1.51.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in MAIA. Corsair Capital Management L.P. acquired a new position in MAIA Biotechnology in the 1st quarter valued at $140,000. Jane Street Group LLC acquired a new position in MAIA Biotechnology in the 4th quarter valued at $120,000. Geode Capital Management LLC raised its stake in MAIA Biotechnology by 9.5% in the 4th quarter. Geode Capital Management LLC now owns 296,740 shares of the company’s stock valued at $454,000 after purchasing an additional 25,684 shares during the last quarter. Ritholtz Wealth Management acquired a new position in MAIA Biotechnology in the 4th quarter valued at $35,000. Finally, Marshall Wace LLP acquired a new position in MAIA Biotechnology in the 2nd quarter valued at $29,000. 5.65% of the stock is owned by institutional investors and hedge funds.

MAIA Biotechnology Company Profile

MAIA Biotechnology, Inc is a clinical‐stage biopharmaceutical company developing a proprietary platform for site‐specific conjugation of monoclonal antibodies with diagnostic and therapeutic radioisotopes. By leveraging precision radiochemistry, the company aims to enhance the safety and efficacy profiles of antibody‐based imaging agents and targeted radiotherapeutics. Its approach is designed to deliver high‐contrast tumor visualization through PET imaging as well as focused cytotoxicity in oncology indications.

The company’s pipeline includes several antibody‐radiotracer candidates optimized for the detection of distinct tumor biomarkers, with preclinical data showing favorable targeting specificity and improved pharmacokinetics compared to conventional methods.